Madrigal Pharmaceuticals, Inc. has secured a $500 million senior secured credit facility from Blue Owl Capital to advance its pipeline focused on treating metabolic dysfunction-associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results